DR. CAROLYN GERHARDT JENKS D.O. NPI 1730447558

NPI Details

DR. Carolyn Gerhardt Jenks, D.O. is a hematology and oncology internal medicine in Tyler, TX with 17 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Carolyn Gerhardt Jenks, D.O. NPI is 1730447558. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

501 SAUNDERS AVE STE 200
TYLER, TX
ZIP 75702-524
Phone: (903) 579-9800
Fax: (903) 592-5988

The NPI 1730447558 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, levoleucovorin, not otherwise specified, 0.5 mg (HCPCS:J0641)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Unclassified drugs (HCPCS:J3490)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev (HCPCS:G6013)
• Magnesium level (HCPCS:83735)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Ct scan of chest with contrast (HCPCS:71260)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Iron binding capacity (HCPCS:83550)
• Ferritin (blood protein) level (HCPCS:82728)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev (HCPCS:G6012)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Iron level (HCPCS:83540)
• Urea nitrogen level to assess kidney function, quantitative (HCPCS:84520)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Liver enzyme (sgot), level (HCPCS:84450)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Liver enzyme (sgpt), level (HCPCS:84460)
• Drawing of blood for a medical problem (HCPCS:99195)
• Phosphatase (enzyme) level, alkaline (HCPCS:84075)
• Total protein level, blood (HCPCS:84155)
• Albumin (protein) level (HCPCS:82040)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Ct scan of chest without contrast (HCPCS:71250)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Ct scan of abdomen and pelvis before and after contrast (HCPCS:74178)

The enumeration date for this NPI number is 4/30/2012 and was last updated on 2/5/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.